Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778360 | 0.81 | GSK3A (0.65) | CLK1DYRK1ACCNB2CDK1CCNB1 | |
| SCHEMBL857278 | 0.81 | CCNB2 (0.68) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL4257337 | 0.79 | EGFR (0.61) | CNR1EGFRSRCFNTAFNTB | |
| SCHEMBL8140328 | 0.78 | HTR6 (0.64) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL6672302 | 0.78 | CNR1 (0.49) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL8326898 | 0.78 | CHEK1 (0.42) | CLK1DYRK1ACCNB2CDK1CCNB1 | |
| SCHEMBL8328144 | 0.78 | CHEK1 (0.42) | CLK1DYRK1AADORA2AADORA1CHEK1 | |
| SCHEMBL1778446 | 0.77 | HTR6 (0.49) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL1779054 | 0.77 | CCNB2 (0.48) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL1780538 | 0.76 | CNR1 (0.47) | CCNB2CDK1CCNB1GSK3BCCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | claimed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| CN-100509811-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| CN-100379734-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2008-04-09 | — | — | CN | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| EP-0509974-B1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | ASTRA AB (SE) | 1999-01-13 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | CLK1 1573/4885DYRK1A 919/4885CCNB2 381/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | CLK1 589/4885DYRK1A 593/4885CCNB2 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.